Home > News > Myelodysplastic Syndromes – The Epigenetic Model for Drug Development?
Haematological Malignancies, Myelodysplastic Syndromes
Read Time: 4 mins

Myelodysplastic Syndromes – The Epigenetic Model for Drug Development?

Published Online: November 25th 2016 European Oncology & Haematology, 2016;12(1):13–4 DOI: https://doi.org/10.17925/EOH.2016.12.01.13
Authors: Guillermo Montalban-Bravo, Guillermo Garcia-Manero
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Application of sequencing technology has advanced our understanding of the molecular landscape of myelodysplastic syndromes (MDS). Recurrent driver mutations in genes implicated in epigenetic regulation, and functional modelling of the disease has proven the importance of epigenetic dysregulation in MDS pathogenesis. Although available therapies such as azacitidine and decitabine are thought to exert their effect by epigenetic modulation, deep understanding of disease biology and development of specific epigenetically targeted therapies is still an area under active research. In this editorial we will focus on the molecular basis of MDS with particular focus on epigenetic dysregulation and new agents under development targeting this group of biological processes.

Keywords

Myelodysplastic syndromes, MDS, epigenetics, targeted therapies

Article:

Epigenetic dysregulation in myelodysplastic syndromes – how important is it?
Our understanding of the biology and pathogenesis of myelodysplastic syndromes (MDS) has evolved dramatically in the last two decades. Evidence of an epigenetic background of the disease identified by a hypermethylation of specific genes and promoter-associated CpG islands was reported in the late 1990s1and first decade of this century.2 Multiple sequencing efforts have shed light in the molecular annotation of the disease3–6 and have allowed to better group and dissect the different entities within this heterogeneous group of diseases.7,8 Dysregulation of epigenetic processes such as DNA methylation, histone modifications, miRNA and splicing machinery are essential in MDS pathogenesis and, in fact, multiple mutations and epimutations in well characterised epigenetically related genes such as DNTM3A, TET2, ASXL1, EZH2, IDH1/2 and splicing factors such as U2AF1, SF3B1, ZRSR2 and SRSF2 have been consistently described.9–12 Functional assays in cellular and murine models exploring the leukemogenic potential of such mutations have also confirmed these findings13–18 As a result of this, despite the complexity and heterogeneity of MDS pathogenesis, MDS can be considered, at least partially, an epigenetic disease.

Interestingly, recent studies by several groups including Jaiwal et al.,19 Xie et al.20 and Genovese et al.21 have confirmed that many of such mutations, particularly DNTM3A, TET2 and ASXL1 mutations, can be identified with increased frequency in elderly individuals with no evidence of haematological malignancy as part of what has been named clonal haematopoiesis of indeterminate potential (CHIP). This is particularly relevant considering haematopoietic stem-cell aging is likely one of the mechanisms implicated in MDS clonal initiation and progression19,22–24 and that these same mutations are known to participate in this aging process. In fact, there is evidence supporting that individuals with CHIP, as those with idiopathic cytopenias of unknown significance (ICUS), characterised by cytopenias with no significant dysplasia and presence of CHIP-like mutations in up to 28% of cases, are at an increased risk of ultimately developing MDS.25,26These findings suggest epigenetic dysregulation is at the base of the progressive biological process driving clonal evolution leading to MDS.

Targeting the epigenome in myelodysplastic syndromes – state of the art and future perspectives
While the above mentioned findings have clearly advanced the knowledgebase of MDS pathophysiology, clear therapeutic and prognostic impact of this data still remains elusive and, despite a few exceptions, has not yet allowed modifying disease treatment. One of such exceptions was the development and subsequent approval by the FDA of azacitidine and decitabine, two cytidine analogues with a potent inhibitory effect of DNA methylation by induction of DNA methyl transferase (DNMT) depletion. Although approval of these agents led to a revolution of the treatment of these patients, reducing and delaying the risk of transformation to acute leukaemia and prolonging survival, only 40% of patients achieve responses to therapy and, in a majority of them, responses tend to be short-lived with eventual loss of response resulting in poor outcomes.27–29 To overcome this, multiple clinical trials evaluating the potential of combinations of new epigenetic modifiers with hypomethylating agents have been conducted. Post-translational modifications of histones by acetylation, methylation or ubiquination represent the most diverse mechanisms implicated in chromatin remodeling and regulation of gene expression30–32with aberrant expression and function of these regulators clearly participating in MDS pathogenesis. Modification of these abnormal histone modifications by histone deacetylase (HDAC) inhibitors has been systematically tested in multiple clinical trials first as monotherapy, and subsequently in combination with azacitidine due to in vitro data suggesting potential synergistic effect of this combination.33 Ever since the initial study assessing the effectiveness of valproic acid in combination with azacitidine,34 multiple other HDAC inhibitors such as vorinostat,35 entinostat,36 panobinostat and, more recently, pracinostat have been explored in combination with azacitidine. However, despite these efforts in trying to improve the outcomes obtained with hypomethylating agents alone, histone Deacetylase inhibitor and hypomethylating agent (HDACi-HMA) combos have failed to significantly improve response rates of survival of patients with MDS. As a result of this, the interest has shifted to alternative strategies exploring not only epigenetic processes but also innate immunity signalling and immune checkpoint regulation amongst others.

Despite these underwhelming results, epigenetic deregulation in MDS is far more complex and heterogeneous than simple DNA hypermethylation or histone acetylation. Although less frequent than in acute leukaemia, approximately 4–12% patients with MDS have clones with detectable mutations in the isocitrate dehydrogenase genes IDH1 and IDH2. Presence of R132 in IDH1, and R140 and R172 mutations in IDH2 induce a disruption in the enzyme catalytic activity inducing a product shift from α-ketoglutarate to 2-hydroxyglutarate which in turn causes inhibition of the ten-eleven-translocation (TET) genes and increased homeobox A (HOXA) activity responsible for a differentiation block. Development of specific inhibitors such as IDH-305 or AG- 120 in the case of IDH1mut, AG-221 in the case of IDH2mut or the dual inhibitor AG-881 have opened the possibility of specifically targeting this alterations. Initial results in patients with acute myeloid leukaemia (AML) and MDS show response rates of 36–41% with 18% complete responses.37,38 This is specially promising in the context of patients with IDH mutations who lose response to hypomethylating

agents due to the absence of available standard therapies and otherwise poor prognosis.

Mutations in genes coding for splicing machinery factors represent the most frequent group of genomic abnormalities in MDS. Insight in the specific biological processes leading to particular disease phenotypes has rapidly evolved in the last 2 years. Mutations in SF3B1, SRSF2, U2AF1 and ZRSR2 rarely co-occur within a same clone and tend to appear in heterozygosis suggesting only limited degrees of abnormal splicing function are compatible with cellular viability. In fact, preliminary data presented in the last American Society of Hematology (ASH) meeting suggests inhibition of splicing machinery induces significantly increased reduction in leukaemia burden in spliceosomemutant leukaemias.39

In view of these advances, dissection of the specific epigenetic abnormalities present in different subsets of MDS will likely lead to a tailored selection of therapy guided by the particular genomic abnormalities present in each individual case (Figure 1).

Article Information:
Disclosure

Guillermo Montalban-Bravo and Guillermo Garcia-Manero have nothing to disclose in relation to this article. This article is a short opinion piece and has not been submitted to external peer reviewers. No funding has been received for the publication of this article.
Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.

Correspondence

Guillermo Garcia-Manero MD, Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77015, US. E: ggarciam@mdanderson.org

Open Access

This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit.

Received

2016-04-07T00:00:00

References

1. Ihalainen J, Pakkala S, Savolainen ER, et al., Hypermethylation of the calcitonin gene in the myelodysplastic syndromes, Leukemia, 1993;7:263–7. 2. Figueroa ME, Skrabanek L, Li Y, et al., MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation, Blood, 2009;114:3448-58. 3. Bejar R, Stevenson K, Abdel-Wahab O, et al., Clinical effect of point mutations in myelodysplastic syndromes, N Engl J Med, 2011;364:2496–506. 4. Papaemmanuil E, Gerstung M, Malcovati L, et al., Clinical and biological implications of driver mutations in myelodysplastic syndromes, Blood, 2013;122:3616–27; quiz 99. 5. Haferlach T, Nagata Y, Grossmann V, et al., Landscape of genetic lesions in 944 patients with myelodysplastic syndromes, Leukemia, 2014;28:241–7. 6. Abdel-Wahab O, Figueroa ME, Interpreting new molecular genetics in myelodysplastic syndromes, Hematology Am Soc Hematol Educ Program, 2012;2012:56–64. 7. Patnaik MM, Lasho TL, Vijayvargiya P, et al., Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia, Blood Cancer J, 2016;6:e385. 8. Malcovati L, Karimi M, Papaemmanuil E, et al., SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts, Blood, 2015;126:233–41. 9. Boultwood J, Perry J, Pellagatti A, et al., Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia, Leukemia, 2010;24:1062–5. 10. Abdel-Wahab O, Mullally A, Hedvat C, et al,. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies, Blood, 2009;114:144–7. 11. Gelsi-Boyer V, Trouplin V, Adelaide J, et al., Mutations of polycombassociated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia, Br J Haematol, 2009;145:788–800. 12. Graubert TA, Shen D, Ding L, et al., Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes, Nat Genet, 2012;44:53–7. 13. Chaturvedi A, Araujo Cruz MM, Jyotsana N, et al., Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML, Blood, 2013;122:2877–87. 14. Chen Q, Chen Y, Bian C, et al., TET2 promotes histone O-GlcNAcylation during gene transcription, Nature, 2013;493:561-4. 15. Challen GA, Sun D, Jeong M, et al., Dnmt3a is essential for hematopoietic stem cell differentiation, Nat Genet, 2012;44:23–31. 16. Davies C, Yip BH, Fernandez-Mercado M, et al., Silencing of ASXL1 impairs the granulomonocytic lineage potential of human CD34(+) progenitor cells, Br J Haematol, 2013;160:842–50. 17. Khan SN, Jankowska AM, Mahfouz R, et al., Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies, Leukemia, 2013;27:1301–9. 18. Jost E, Lin Q, Weidner CI, et al., Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia, Leukemia, 2014;28:1227–34 . 19. Jaiswal S, Fontanillas P, Flannick J, et al., Age-related clonal hematopoiesis associated with adverse outcomes, N Engl J Med, 2014;371:2488–98. 20. Xie M, Lu C, Wang J, et al., Age-related mutations associated with clonal hematopoietic expansion and malignancies, Nat Med, 2014;20:1472–8. 21. Genovese G, Kahler AK, Handsaker RE, et al., Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence, N Engl J Med, 2014;371:2477–87. 22. Nilsson L, Eden P, Olsson E, et al., The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes, Blood, 2007;110:3005–14. 23. Will B, Zhou L, Vogler TO, et al., Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations, Blood, 2012;120:2076–86. 24. Beerman I, Rossi DJ, Epigenetic regulation of hematopoietic stem cell aging, Exp Cell Res, 2014;329:192–9. 25. Cargo CA, Rowbotham N, Evans PA, et al., Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression, Blood, 2015;126:2362–5. 26. Kwok B, Hall JM, Witte JS, et al., MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance, Blood, 2015;126:2355–61. 27. Jabbour E, Garcia-Manero G, Batty N, et al., Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy, Cancer, 2010;116:3830–4. 28. Prebet T, Gore SD, Esterni B, et al., Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure, J Clin Oncol, 2011;29:3322–7. 29. Lee JH, Choi Y, Kim SD, et al., Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome, Eur J Haematol, 2015;94:546–53. 30. Falkenberg KJ, Johnstone RW, Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders, Nat Rev Drug Discov, 2014;13:673–91. 31. Kouzarides T, Chromatin modifications and their function, Cell, 2007;128:693–705. 32. Berger SL, The complex language of chromatin regulation during transcription, Nature, 2007;447:407–12. 33. Cameron EE, Bachman KE, Myohanen S, et al., Synergy of demethylation and histone deacetylase inhibition in the reexpression of genes silenced in cancer, Nat Genet, 1999;21:103–7. 34. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al., Phase 1/2 study of the combination of 5-aza-2’-deoxycytidine with valproic acid in patients with leukemia, Blood, 2006;108:3271–9. 35. Verma A, Odchimar-Reissig R, Feldman EJ, et al., A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium, Blood, 2013;122:386. 36. Prebet T, Sun Z, Ketterling RP, et al., Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study, Br J Haematol, 2016;172:384–91. 37. DiNardo C, de Botton S, Pollyea DA, et al., Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study, Blood, 2015;126:1306. 38. Stein EM, DiNardo C, Altman JK, et al., Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial, Blood, 2015;126:323. 39. Lee SC-W, Dvinge H, Kim E, et al., Therapeutic Targeting of Spliceosomal Mutant Myeloid Leukemias through Modulation of Splicing Catalysis, Blood, 2015;126:4.

Further Resources

Share this Article
Related Content In Myelodysplastic Syndromes
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72